Northwestern Univ., Chicago, IL. Presents a review of the endocrine treatment of breast and prostate cancer by the originators, a model for making new discoveries in the chemoprevention of cancer, a synthesis of history and clinical practice, and a guide for progress. DNLM: Breast Neoplasms--drug therapy.
Author(s): V. Craig Jordan, B.J.A. Furr
Series: Cancer drug discovery and development
Edition: 1st
Publisher: Humana Press
Year: 2002
Language: English
Pages: 423
City: Totowa, N.J
ASD ZONE......Page 1
CONTENTS......Page 12
1 An Introduction to the Regulation of Sex Steroids for the Treatment of Cancer......Page 18
Part I: Preclinical Antiestrogens......Page 31
2 Antiestrogens and the Cell Cycle......Page 32
3 Drug Resistance to Antiestrogens......Page 61
4 Mechanisms of Liver Carcinogenesis by Antiestrogens......Page 83
5 The Effects of Triphenylethylene Antiestrogens on Parameters of Multistage Hepatocarcinogenesis in the Rat......Page 96
6 Preclinical Studies of Raloxifene and Related Compounds......Page 145
7 Pure Antiestrogens......Page 172
Part II: Antiestrogens: Clinical......Page 193
8 Tamoxifen for the Treatment of Breast Cancer......Page 194
9 Clinical Utility of New Antiestrogens......Page 203
10 Breast Cancer Prevention with Antiestrogens......Page 221
Part III: Inhibition of Estrogen Synthesis......Page 240
11 Aromatase Inhibitors......Page 241
12 Clinical Utility of Aromatase Inhibitors......Page 270
13 LH-RH Agonists for the Treatment of Breast Cancer:......Page 297
Part IV: Androgens and Androgen Withdrawal......Page 313
14 Molecular Action of Androgens......Page 314
15 Steroidal Antiandrogens......Page 328
16 Nonsteroidal Antiandrogens......Page 350
17 LH-RH Agonist Role in Prostate Cancer Management......Page 372
Part V: Perspective on Progress......Page 386
18 Recent Progress in Breast Cancer Research......Page 387
Index......Page 411
